Challenge
A well-capitalized, private biotech company with a drug discovery platform identified multiple first-in-class and best-in-class compounds targeting critical pathways widely involved in inflammatory and fibrotic diseases. As lead compounds progressed toward the development phase, the company was considering a broad spectrum of disorders as initial and follow on targets for therapy, including liver fibrotic disorders, idiopathic pulmonary fibrosis, renal fibrosis, and inflammatory bowel disease. The company desired a chief medical officer (CMO) with deep development experience in the broad area of fibrotic disease including liver, gastrointestinal, renal, and lung disease and organizational experience in the roles and responsibilities of a CMO.
Solution
Alacrita’s acting CMO is a board-certified gastroenterologist/hepatologist with over ten years’ experience in the biotech and large pharma environment, including as CMO of a top-10 pharmaceutical company. He is committed to spending 16-24 hours per week embedded in the company, with significant time on site, to ensure a high impact engagement. He has diverse responsibilities including advising the CEO and other officers on strategic clinical decisions, assessing disease targets across the broad area of fibrosis for the robust discovery pipeline, supporting biomarker discovery team, leading and designing clinical development, designing clinical trials, supporting submission of INDs and IMPDs, and beginning to fit out the development organization to prepare for entry into clinical trials.
Alacrita’s consulting team provides interim chief medical officer support for companies who are seeking a full-time chief medical officer or have a short term need where a full-time chief medical officer cannot be justified.
More Information:
Project Lead: Peter Traber
Key Services: Product Development, Clinical Development Support
For more information on this Alacrita service please email ptraber@alacrita.com